Dhingra Ankur 4
4 · Summit Therapeutics Inc. · Filed Aug 17, 2022
Insider Transaction Report
Form 4
Dhingra Ankur
Chief Financial Officer
Transactions
- Purchase
Common Stock
2022-08-16$0.97/sh+11,557$11,210→ 38,057 total - Purchase
Common Stock
2022-08-16$0.97/sh+24,658$23,918→ 38,196 total(indirect: By Trust)
Footnotes (2)
- [F1]Represents the number of shares of Common Stock that the Reporting Person purchased in the Issuer's rights offering.
- [F2]The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.